Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry
© 2021. The Author(s)..
The growing prevalence of opioid use disorder (OUD) constitutes an urgent health crisis. Ample evidence indicates that risk for OUD is heritable. As a surrogate (or proxy) for OUD, we explored the genetic basis of using prescription opioids 'not as prescribed'. We hypothesized that misuse of opiates might be a heritable risk factor for OUD. To test this hypothesis, we performed a genome-wide association study (GWAS) of problematic opioid use (POU) in 23andMe research participants of European ancestry (N = 132,113; 21% cases). We identified two genome-wide significant loci (rs3791033, an intronic variant of KDM4A; rs640561, an intergenic variant near LRRIQ3). POU showed positive genetic correlations with the two largest available GWAS of OUD and opioid dependence (rg = 0.64, 0.80, respectively). We also identified numerous additional genetic correlations with POU, including alcohol dependence (rg = 0.74), smoking initiation (rg = 0.63), pain relief medication intake (rg = 0.49), major depressive disorder (rg = 0.44), chronic pain (rg = 0.42), insomnia (rg = 0.39), and loneliness (rg = 0.28). Although POU was positively genetically correlated with risk-taking (rg = 0.38), conditioning POU on risk-taking did not substantially alter the magnitude or direction of these genetic correlations, suggesting that POU does not simply reflect a genetic tendency towards risky behavior. Lastly, we performed phenome- and lab-wide association analyses, which uncovered additional phenotypes that were associated with POU, including respiratory failure, insomnia, ischemic heart disease, and metabolic and blood-related biomarkers. We conclude that opioid misuse can be measured in population-based cohorts and provides a cost-effective complementary strategy for understanding the genetic basis of OUD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Molecular psychiatry - 26(2021), 11 vom: 02. Nov., Seite 6209-6217 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sanchez-Roige, Sandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Analgesics, Opioid |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 08.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41380-021-01335-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33266967X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33266967X | ||
| 003 | DE-627 | ||
| 005 | 20231225220036.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41380-021-01335-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM33266967X | ||
| 035 | |a (NLM)34728798 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sanchez-Roige, Sandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 08.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a The growing prevalence of opioid use disorder (OUD) constitutes an urgent health crisis. Ample evidence indicates that risk for OUD is heritable. As a surrogate (or proxy) for OUD, we explored the genetic basis of using prescription opioids 'not as prescribed'. We hypothesized that misuse of opiates might be a heritable risk factor for OUD. To test this hypothesis, we performed a genome-wide association study (GWAS) of problematic opioid use (POU) in 23andMe research participants of European ancestry (N = 132,113; 21% cases). We identified two genome-wide significant loci (rs3791033, an intronic variant of KDM4A; rs640561, an intergenic variant near LRRIQ3). POU showed positive genetic correlations with the two largest available GWAS of OUD and opioid dependence (rg = 0.64, 0.80, respectively). We also identified numerous additional genetic correlations with POU, including alcohol dependence (rg = 0.74), smoking initiation (rg = 0.63), pain relief medication intake (rg = 0.49), major depressive disorder (rg = 0.44), chronic pain (rg = 0.42), insomnia (rg = 0.39), and loneliness (rg = 0.28). Although POU was positively genetically correlated with risk-taking (rg = 0.38), conditioning POU on risk-taking did not substantially alter the magnitude or direction of these genetic correlations, suggesting that POU does not simply reflect a genetic tendency towards risky behavior. Lastly, we performed phenome- and lab-wide association analyses, which uncovered additional phenotypes that were associated with POU, including respiratory failure, insomnia, ischemic heart disease, and metabolic and blood-related biomarkers. We conclude that opioid misuse can be measured in population-based cohorts and provides a cost-effective complementary strategy for understanding the genetic basis of OUD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Analgesics, Opioid |2 NLM | |
| 650 | 7 | |a Jumonji Domain-Containing Histone Demethylases |2 NLM | |
| 650 | 7 | |a EC 1.14.11.- |2 NLM | |
| 650 | 7 | |a KDM4A protein, human |2 NLM | |
| 650 | 7 | |a EC 1.5.- |2 NLM | |
| 700 | 1 | |a Fontanillas, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Jennings, Mariela V |e verfasserin |4 aut | |
| 700 | 1 | |a Bianchi, Sevim B |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Yuye |e verfasserin |4 aut | |
| 700 | 1 | |a Hatoum, Alexander S |e verfasserin |4 aut | |
| 700 | 1 | |a Sealock, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Davis, Lea K |e verfasserin |4 aut | |
| 700 | 1 | |a Elson, Sarah L |e verfasserin |4 aut | |
| 700 | 0 | |a 23andMe Research Team |e verfasserin |4 aut | |
| 700 | 1 | |a Palmer, Abraham A |e verfasserin |4 aut | |
| 700 | 1 | |a Agee, Michelle |e investigator |4 oth | |
| 700 | 1 | |a Alipanahi, Babak |e investigator |4 oth | |
| 700 | 1 | |a Auton, Adam |e investigator |4 oth | |
| 700 | 1 | |a Bell, Robert K |e investigator |4 oth | |
| 700 | 1 | |a Bryc, Katarzyna |e investigator |4 oth | |
| 700 | 1 | |a Furlotte, Nicholas A |e investigator |4 oth | |
| 700 | 1 | |a Hinds, David A |e investigator |4 oth | |
| 700 | 1 | |a Huber, Karen E |e investigator |4 oth | |
| 700 | 1 | |a Kleinman, Aaron |e investigator |4 oth | |
| 700 | 1 | |a Litterman, Nadia K |e investigator |4 oth | |
| 700 | 1 | |a McCreight, Jennifer C |e investigator |4 oth | |
| 700 | 1 | |a McIntyre, Matthew H |e investigator |4 oth | |
| 700 | 1 | |a Mountain, Joanna L |e investigator |4 oth | |
| 700 | 1 | |a Noblin, Elizabeth S |e investigator |4 oth | |
| 700 | 1 | |a Northover, Carrie A M |e investigator |4 oth | |
| 700 | 1 | |a Pitts, Steven J |e investigator |4 oth | |
| 700 | 1 | |a Sathirapongsasuti, J Fah |e investigator |4 oth | |
| 700 | 1 | |a Sazonova, Olga V |e investigator |4 oth | |
| 700 | 1 | |a Shelton, Janie F |e investigator |4 oth | |
| 700 | 1 | |a Shringarpure, Suyash |e investigator |4 oth | |
| 700 | 1 | |a Tian, Chao |e investigator |4 oth | |
| 700 | 1 | |a Tung, Joyce Y |e investigator |4 oth | |
| 700 | 1 | |a Vacic, Vladimir |e investigator |4 oth | |
| 700 | 1 | |a Wilson, Catherine H |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular psychiatry |d 1997 |g 26(2021), 11 vom: 02. Nov., Seite 6209-6217 |w (DE-627)NLM09062694X |x 1476-5578 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2021 |g number:11 |g day:02 |g month:11 |g pages:6209-6217 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41380-021-01335-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2021 |e 11 |b 02 |c 11 |h 6209-6217 | ||